New medical insurance reimbursement policy for Avatrombopag in 2025

In 2025, China’s medical insurance policy for avatrombopag (Avatrombopag) will continue to provide certain financial support to patients. As a targeted drug for the treatment of chronic idiopathic thrombocytopenic purpura (ITP), avatrombopag has been officially included in the medical insurance system. This means that eligible patients can enjoy medical insurance reimbursement when purchasing the drug, reducing the patient's treatment burden. The specific amount of medical insurance reimbursement will vary according to local policies, so patients need to consult the local hospital pharmacy to confirm the actual reimbursement amount.

Currently, avatrombopag is available in two specifications in China: 20mg 10 tablets and 20mg 15 tablets, with prices of approximately more than 5,000 yuan and 7 to 8,000 yuan respectively. Since the drug has been included in medical insurance, patients can receive a certain percentage of reimbursement within the scope of medical insurance, thus greatly reducing the actual burden of the drug. However, since the specific medical insurance reimbursement ratio may vary depending on the region, medical insurance policy and hospital, it is best for patients to consult their local pharmacy for detailed medical insurance information and reimbursement procedures before purchasing medicines.

In addition to original drugs, there are also some generic drugs available on the market, mainly Lao and Bangladeshi versions. The prices of these generic drugs are much lower than those of original drugs. The price of generic drugs in Laos and Bangladesh is about a few hundred yuan, which is basically the same as the ingredients of the original drugs, but the cost is greatly reduced. This is a viable option for some patients with heavy financial burdens. However, patients should confirm whether generic drugs are suitable for their treatment plan under the guidance of their doctor.

In general,2025 the medical insurance reimbursement policy for avatrombopag provides patients with relatively stable financial support. Patients can choose to purchase original drugs or generic drugs according to their personal circumstances and enjoy the discounts brought by medical insurance. However, due to the price difference, patients should comprehensively consider drug effects, financial conditions, and medical insurance policies when making choices to ensure the best treatment effect and cost-effectiveness.

Reference materials:https://go.drugbank.com/drugs/DB11995